Abstract The Traumatic Brain Injury Endpoints Development (TED) Initiative is a 5-year,
Department of Defense–funded project that is working toward the ultimate goal of …

Traumatic brain injury (TBI) is among the leading causes of death and disability worldwide,
with enormous negative social and economic impacts. The heterogeneity of TBI combined …

New neuroprotective therapies for severe traumatic brain injury (TBI) have not translated
from pre-clinical to clinical success. Numerous explanations have been suggested in both …

A biomarker is a qualitative and quantitative biological substance or characteristic that
defines a certain pathological condition and may give indications on disease severity and …

Current approaches have failed to yield success in the translation of neuroprotective
therapies from the pre-clinical to the clinical arena for traumatic brain injury (TBI). Numerous …

Traumatic brain injury (TBI) was the signature injury in both the Iraq and Afghan wars and
the magnitude of its importance in the civilian setting is finally being recognized. Given the …

Recent biomarker innovations hold potential for transforming diagnosis, prognostic
modeling, and precision therapeutic targeting of traumatic brain injury (TBI). However, many …

Despite extensive research focusing on development of therapeutics for traumatic brain
injury (TBI) and success in preclinical trials, numerous phase 3 clinical trials have been …

Despite the large number of promising neuroprotective agents identified in experimental
traumatic brain injury (TBI) studies, none has yet shown meaningful improvements in long …

Traumatic brain injury (TBI) is a global public health problem that affects the long-term
cognitive, physical, and psychological health of patients, while also having a major impact …